# A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers

> **NCT02919696** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 26 (actual)

## Conditions studied

- Advanced Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT02919696
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-07
- **Primary completion:** 2018-11-23
- **Final completion:** 2019-09-03
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02919696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02919696, "A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02919696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*